Feng Yanping, Xiang Qingqing, Dai Xianzhen, Ma Pingping, Liu Bo, Tan Youguo
The Zigong Affiliated Hospital, Southwest Medical University, Zigong, China.
Department of Auxiliary Examination, Zigong Mental Health Center, Zigong, China.
Medicine (Baltimore). 2025 May 16;104(20):e42505. doi: 10.1097/MD.0000000000042505.
Lithium carbonate, a mood stabilizer, is most commonly used for the treatment and prevention of mania and bipolar disorder. Common renal side effects include polyuria and polydipsia. However, when combined with other psychotropic medications that have sedative properties, lithium may increase the risk of nocturnal enuresis.
A 12-year-old girl experienced recurrent major depressive episodes with psychotic symptoms. Her clinical presentation was complex, including depressed mood, irritability, suicidal ideation or behavior, and partial psychotic features. During treatment, she frequently reported polydipsia, polyuria, and nocturnal enuresis.
Based on the International Classification of Diseases, 10th Edition, the patient was diagnosed with major depressive disorder with psychotic symptoms (F32.3) and enuresis not due to a physical disorder (F98.0).
In addition to receiving antidepressants, antipsychotics, benzodiazepines, and modified electroconvulsive therapy, she was also intermittently treated with lithium carbonate extended-release tablets, with a maximum daily dose of 1.2 g. No pathophysiological abnormalities were identified through imaging examinations in relation to her nocturnal enuresis. After suspecting a link between her enuresis and lithium, her nocturnal enuresis resolved following the discontinuation of lithium carbonate extended-release tablets.
During the 4-month follow-up, the patient remained free of nocturnal enuresis, while her depressive and psychotic symptoms significantly subsided.
Psychiatrists should be aware of the possibility of lithium-induced nocturnal enuresis when polyuria and polydipsia emerge during lithium treatment, particularly in children and adolescents receiving concomitant psychotropic medications with sedative properties.
碳酸锂作为一种心境稳定剂,最常用于治疗和预防躁狂症和双相情感障碍。常见的肾脏副作用包括多尿和烦渴。然而,当与其他具有镇静作用的精神药物合用时,锂可能会增加夜间遗尿的风险。
一名12岁女孩经历了伴有精神病症状的复发性重度抑郁发作。她的临床表现复杂,包括情绪低落、易怒、自杀观念或行为以及部分精神病特征。在治疗期间,她频繁报告烦渴、多尿和夜间遗尿。
根据《国际疾病分类》第10版,该患者被诊断为伴有精神病症状的重度抑郁症(F32.3)和非躯体疾病所致的遗尿症(F98.0)。
除了接受抗抑郁药、抗精神病药、苯二氮䓬类药物和改良电休克治疗外,她还间断服用碳酸锂缓释片,最大日剂量为1.2克。通过影像学检查未发现与她夜间遗尿相关的病理生理异常。在怀疑她的遗尿与锂有关后,停用碳酸锂缓释片后她的夜间遗尿症状消失。
在4个月的随访期间,患者未再出现夜间遗尿,同时她的抑郁和精神病症状明显减轻。
当锂治疗期间出现多尿和烦渴时,精神科医生应意识到锂诱发夜间遗尿的可能性,尤其是在同时接受具有镇静作用的精神药物治疗的儿童和青少年中。